A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma

Background Several studies have suggested that chemotherapy prolonged survival in patients with metastatic or recurrent small bowel adenocarcinoma (SBA); however, there is still no standard chemotherapy regimen. Here, we evaluated the efficacy and safety of a 5-fluorouracil (5-FU)/L-leucovorin (l-LV...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of clinical oncology 2017-10, Vol.22 (5), p.905-912
Hauptverfasser:	Horimatsu, Takahiro, Nakayama, Norisuke, Moriwaki, Toshikazu, Hirashima, Yoshinori, Fujita, Mikio, Asayama, Masako, Moriyama, Ichiro, Nakashima, Koji, Baba, Eishi, Kitamura, Hiroshi, Tamura, Takao, Hosokawa, Ayumu, Yoshimura, Kenichi, Muto, Manabu
Format:	Artikel
Sprache:	eng
Schlagworte:	5-Fluorouracil Adenocarcinoma Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - pathology Adenocarcinoma - surgery Adult Aged Anemia Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Asian Continental Ancestry Group Bowel disease Cancer Research Chemotherapy Disease-Free Survival Drug therapy Duodenum Female Fluorouracil - administration & dosage Fluorouracil - therapeutic use Humans Intestinal Neoplasms - drug therapy Intestinal Neoplasms - mortality Intestinal Neoplasms - pathology Intestine, Small - pathology Jejunum Leucovorin - administration & dosage Leucovorin - therapeutic use Male Medicine Medicine & Public Health Metastases Metastasis Middle Aged Neutropenia Neutropenia - chemically induced Oncology Organoplatinum Compounds - administration & dosage Organoplatinum Compounds - therapeutic use Original Original Article Oxaliplatin Peripheral neuropathy Small intestine Stenosis Surgical Oncology Survival Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!